WARSAW – Zimmer Biomet announced the U.S. Food and Drug Administration has approved clearance of the ROSA Hip System for robotically-assisted direct anterior total hip replacement.
ROSA Hip is the fourth robotic system introduced by Zimmer Biomet and adds to the Company’s comprehensive ROSA Robotics portfolio, which includes the ROSA Knee System for total and partial knee arthroplasty, and another for neurosurgical and spine procedures.
ROSA Hip is the newest addition to ZBEdge, Zimmer Biomet’s suite of integrated digital and robotic technologies purposefully engineered to deliver transformative data-powered clinical insights, shared seamlessly across the patient journey, and with the goal of improving patient outcomes.
“We’re excited to announce the FDA clearance of ROSA Hip, and to now offer one of the most comprehensive orthopedic robotic solutions through a single, multiple application platform,” said Ivan Tornos, Chief Operating Officer at Zimmer Biomet.
Designed to seamlessly adapt to a surgeon’s existing workflow, ROSA Hip aims to assist direct anterior surgeons with preparation, positioning and component impaction, while intra-operatively quantifying cup orientation, leg length and offset. Intra-operative data collected by ROSA Hip is combined with a proprietary remote care management platform.=
“ROSA Hip will allow surgeons to retain complete control over case planning and execution, while providing real-time data and visualization tools,” said Atul Kamath, M.D., Director, Center for Hip Preservation at the Cleveland Clinic and a ROSA Hip developer surgeon.
To learn more about ROSA Hip, visit zimmerbiomet.com/ROSAHip.